8-K current report · filed Oct 29, 2026

Mineralys Therapeutics, Inc. (MLYS) 8-K Current Report: October 29, 2026

Item 1.02Item 1.01MLYS overview

Short answer

Mineralys Therapeutics, Inc. (MLYS) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 1.01 (Entry into a Material Definitive Agreement). Mineralys now owns lorundrostat-related patents and know-how previously licensed from Tanabe.

Mineralys Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Mineralys now owns lorundrostat-related patents and know-how previously licensed from Tanabe
  • License termination removes ongoing license framework but preserves Tanabe milestone payment obligations
  • Up to $265.0 million remains payable upon first sale, sales targets, or second-indication commercialization
  • $100.0 million could accelerate upon a change of control or exclusive U.S. partnering transaction
  • Tanabe retains Japan negotiation rights until applicable milestone payments are achieved and paid

Item 1.02 · Termination of a Material Definitive Agreement

  • License Agreement termination confirmed, with details incorporated from Item 1.01
  • No material early termination penalties, limiting immediate cash impact
  • Termination may alter Mineralys’s strategic or development plans tied to the licensed program

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Mineralys Therapeutics, Inc. 8-K filings

Get the next MLYS 8-K as it lands

Follow MLYS for push alerts, or ask the research agent what this filing means.